{
  "metadata": {
    "case_id": 70,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T18:23:22.663715",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/70_NCT03136861.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/70_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 7,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.83,
          0.35
        ],
        [
          0.05,
          0.76
        ],
        [
          0.62,
          0.4
        ],
        [
          0.62,
          0.4
        ],
        [
          0.6,
          0.45
        ],
        [
          0.4,
          0.32
        ],
        [
          0.52,
          0.6
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.83,
          "status": "matched",
          "ref_item": {
            "label": "Secukinumab 150 mg (Group A)",
            "type": "EXPERIMENTAL",
            "description": "Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4",
            "interventionNames": [
              "Biological: AIN457"
            ]
          },
          "pred_item": {
            "label": "Group A: Secukinumab 150 mg",
            "type": "EXPERIMENTAL",
            "description": "Patients randomized to receive secukinumab 150 mg in Treatment Period 1 (baseline to Week 8). At Week 8, responders (average spinal pain score <4) continued with secukinumab 150 mg (Arm A1), whereas non-responders were re-randomized either to secukinumab 150 mg (Arm A2) or to secukinumab 300 mg (Arm A3) using an up-titration approach for Treatment Period 2.",
            "interventionNames": [
              "Drug: Secukinumab 150 mg",
              "Drug: Secukinumab 300 mg"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.76,
          "status": "matched",
          "ref_item": {
            "label": "Placebo (Group B)",
            "type": "PLACEBO_COMPARATOR",
            "description": "Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": {
            "label": "Group B: Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Patients randomized to receive placebo in Treatment Period 1 (baseline to Week 8). At Week 8, patients were re-randomized to either secukinumab 150 mg (Arm B1) or secukinumab 300 mg (Arm B2) in a 1:1 ratio for Treatment Period 2.",
            "interventionNames": [
              "Drug: Placebo",
              "Drug: Secukinumab 150 mg",
              "Drug: Secukinumab 300 mg"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Arm A1",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Arm A2",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Arm A3",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20",
            "interventionNames": [
              "Biological: AIN457"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 5,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Arm B1",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20",
            "interventionNames": [
              "Biological: AIN457",
              "Drug: AIN457 Placebo"
            ]
          },
          "pred_item": null
        },
        {
          "ref_idx": 6,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "label": "Arm B2",
            "type": "ACTIVE_COMPARATOR",
            "description": "Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20",
            "interventionNames": [
              "Biological: AIN457"
            ]
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.82,
          0.9,
          0.2
        ],
        [
          0.6,
          0.4,
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "AIN457",
            "description": "anti IL-17a monoclonal antibody",
            "armGroupLabels": [
              "Arm A1",
              "Arm A2",
              "Arm A3",
              "Arm B1",
              "Arm B2",
              "Placebo (Group B)",
              "Secukinumab 150 mg (Group A)"
            ],
            "otherNames": [
              "secukinumab"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Secukinumab 300 mg",
            "description": "Administered by subcutaneous injections using 1 mL pre-filled syringes.",
            "armGroupLabels": [
              "Group A: Secukinumab 150 mg",
              "Group B: Placebo"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 2,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "AIN457 Placebo",
            "description": "Placebo matching AIN457",
            "armGroupLabels": [
              "Arm A1",
              "Arm A2",
              "Arm B1",
              "Placebo (Group B)"
            ],
            "otherNames": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Administered by subcutaneous injections using 1 mL pre-filled syringes. Identical in packaging, labelling, schedule of administration, and appearance to the active drug.",
            "armGroupLabels": [
              "Group B: Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.99
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8 (Treatment Period 1)",
            "description": "The spinal pain numerical rating scale (NRS) is an 11-point scale to assess pain intensity in patients who are able to self-report. It is an 11-point scale from 0-10: 1) \"0\" = no pain. 2) \"10\" = the most intense pain imaginable. To calculate the average spinal pain, the patient was asked to answer 2 questions to get 2 pain ratings, the total spinal pain corresponding to the intensity of spinal pain experienced on an average over 24 hours during the previous week and the nocturnal back pain corresponding to the intensity of spinal pain experienced on an average over the night during the previous week.",
            "timeFrame": "Week 8"
          },
          "pred_item": {
            "measure": "Proportion of patients achieving an average spinal pain score of <4",
            "description": "Assessed using a 0â€“10 numerical rating scale (NRS). The average spinal pain score is the average of the total score (pain at any time) and the nocturnal score (pain during the night).",
            "timeFrame": "Week 8"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.99
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Participants With a Bath Ankylosing Spondylitis Disease Activity Index Score Below 4 at Week 8 (Treatment Period 1)",
            "description": "The Bath ankylosing spondylitis disease activity index (BASDAI) consists of a 0 through 10 scale, which is used to answer 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.",
            "timeFrame": "Week 8"
          },
          "pred_item": {
            "measure": "Proportion of patients achieving a BASDAI score of <4",
            "description": "Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of less than 4.",
            "timeFrame": "Week 8"
          }
        }
      ]
    }
  ]
}